2020-2021 Nationwide Blood Donor Seroprevalence Survey Combined Infection- and Vaccination-Induced Seroprevalence Estimates

CDC is collaborating with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), Westat Inc., and numerous blood collection organizations across the United States to conduct a nationwide COVID-19 seroprevalence survey of blood donors. This is the largest nationwide COVID-19 seroprevalence survey to date. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Combined seroprevalence estimates the proportion of the population with evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both. It estimates the proportion of the population with some presumed protection against infection with the virus that causes COVID-19. The term “combined seroprevalence” refers to the combined infection- and vaccination-induced SARS-CoV-2 seroprevalences. This is the population that has anti-S antibodies, regardless of the presence of anti-N antibodies.

This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence

Additional information is available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html

疾病控制与预防中心（CDC）正与国家卫生研究院（NIH）、食品药品监督管理局（FDA）、Vitalant研究学院（VRI）、Westat公司以及美国众多血液采集机构携手合作，开展全国范围内的COVID-19血清流行病学调查。此项调查是目前为止规模最大的全国性COVID-19血清流行病学调查。去识别化的血液样本被检测以识别针对SARS-CoV-2的抗体，旨在更深入地理解美国人群中具有针对SARS-CoV-2（引发COVID-19的病毒）抗体比例，并追踪这一比例随时间的变化。SARS-CoV-2感染和目前在美国使用的COVID-19疫苗均能导致抗刺突（抗S）抗体的产生，但仅感染能够导致抗核壳（抗N）抗体的产生。综合血清流行病学估算的是具有先前SARS-CoV-2感染、COVID-19疫苗接种或两者兼有的群体比例。它估算的是具有一定预防COVID-19病毒感染保护作用的群体比例。‘综合血清流行病学’一词指由感染和疫苗接种引起的SARS-CoV-2血清流行病学。这是指具有抗S抗体的群体，无论是否存在抗N抗体。

本链接链接至一个网页，展示全国血液捐献者血清流行病学调查数据。它提供了一个可在https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence处访问的交互式可视化。

更多相关信息请查阅：https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html